LENSAR Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q4 Revenue: $16 million, a 4% decline year-over-year, primarily due to lower system sales.

Full Year Revenue: Increased by 9% to $61.1 million.

Recurring Revenue: Grew 15% year-over-year to $46.3 million, with Q4 recurring revenue at $12.7 million, annualizing to over $50 million.

Procedure Volume: Increased approximately 20% year-over-year in Q4, with full-year procedures growing 22% to surpass 206,000 globally.

Installed Base: Expanded by nearly 50% year-over-year to over 200 ALLY systems.

Gross Margin: Q4 gross margin was 43%, slightly up from 42% in Q4 2024; full-year gross margin declined to 46% from 48% in 2024.

Adjusted EBITDA: Positive adjusted EBITDA of $595,000 in Q4, indicating operating cash flow positivity.

2Strategic Updates and Business Highlights

The planned acquisition by Alcon was terminated due to FTC concerns, but LENSAR received a $10 million transaction deposit, enhancing its cash position.

The company is refocusing on growth and re-engaging with key stakeholders after a year of uncertainty.

LENSAR has gained significant market share, increasing from 14% to 23.4% in the U.S. cataract procedure market since the launch of the ALLY system.

The company emphasizes its innovative technology, which includes machine learning and improved patient outcomes, distinguishing it from first-generation competitors.

3Forward Guidance and Outlook

LENSAR expects a gradual return to historical operating performance in 2026, with a focus on accelerating revenue growth, maintaining cost discipline, and enhancing cash flow.

The company anticipates a 10% increase in cash-based operating expenses for 2026, primarily for commercial activities.

Future growth is expected to be driven by increased system placements and utilization, particularly outside the U.S. as distributors re-engage.

4Bad News, Challenges, or Points of Concern

The termination of the acquisition has created a period of uncertainty, which previously impacted customer decision-making and international sales.

Q4 system sales were notably lower, with only 12 systems sold in the U.S. and just 1 internationally, down from 10 in Q4 2024.

The company faces competitive pressures, particularly from larger firms with more extensive resources and product bundling capabilities.

There is a cautious outlook regarding the speed of recovery in international markets, with potential delays in tender processes and distributor re-engagement.

5Notable Q&A Insights

Management acknowledged that rebuilding momentum in international markets will take several quarters, emphasizing the need for patience as distributors re-engage.

There is an expectation of a shift towards more lease-based placements in the U.S., reflecting a changing sales dynamic.

The company is exploring new markets, including Australia and New Zealand, for potential expansion, while also looking to regain momentum in Southeast Asia and Europe.

Management expressed confidence in the long-term value of the ALLY system and its ability to drive growth despite current challenges.